Clinical Trial: Resmiterom Efficacy & Safety in Patients With MASH

U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07249788) titled 'Resmiterom Efficacy & Safety in Patients With MASH' on Nov. 18.

Brief Summary: Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.

Study Start Date: Nov. 30

Study Type: INTERVENTIONAL

Condition: MASH - Metabolic Dysfunction-Associated Steatohepatitis

Intervention: DRUG: Resmetirom

1st FDA approved MASH therapy

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Nabiqasim Industries (Pvt) Ltd

Information provided by (Responsible Party): Dr Hussain Abidi, Nabiqasim Industries (Pvt) Ltd

Published by HT Digital Content Services w...